| Date | Title | Description |
| 17.09.2026 | US healthtech company Massive Bio expands Asia footprint with South Korea market push | Massive Bio appoints Intralink to support its expansion into South Korea's oncology sector.
Appoints Intralink to engage hospitals, diagnostic labs & oncologists BOCA RATON, FL, UNITED STATES, September 17, 2026 /EINPresswire.com/ -- US... |
| 09.09.2026 | Massive Bio and PrecisCa Announce Strategic Partnership to Expand Cancer Patient Access to Clinical Trials Across the US | Massive Bio and PrecisCa announce a strategic partnership to expand cancer patient access to clinical trials across the U.S.
Collaboration pairs Massive Bio's AI trial matching and concierge support with PrecisCa's provider network to boost... |
| 04.08.2026 | Massive Bio Makes Inaugural Strategic Investment in Rivvi to Build End-to-End AI Engagement Infrastructure in Healthcare | Massive Bio announces its inaugural strategic investment in Rivvi to build end-to-end AI engagement infrastructure for healthcare.
Investment links prospectively validated oncology intelligence with a healthcare-native agentic AI layer movi... |
| 29.07.2026 | Massive Bio and QC Healthcare Announce National Collaboration to Transform Cancer Patient Access | Massive Bio and QC Healthcare team up to transform cancer patient access to precision oncology.
AI-powered clinical trial matching meets nationwide telehealth to expand cancer care access - trial matching stays free to patients. BOCA RATON,... |
| 27.07.2026 | Massive Bio and GELL Announce Partnership to Advance Research, Education, and AI Across Latin America and the U.S. | Massive Bio and GELL announce a strategic partnership to advance oncology research, medical education, and AI-driven precision medicine across Latin America and the United States.
Collaboration pairs GELL's investigator network with Massive... |
| 20.07.2026 | Massive Bio Partners with FOMAT to Expand Cancer Patient Prescreening for Clinical Trial Access | Massive Bio partners with FOMAT Medical Research to expand AI-driven cancer patient prescreening, connecting more patients to clinical trial opportunities.
Massive Bio partners with FOMAT, the largest U.S. Embedded Research Organization, to... |
| 13.07.2026 | Massive Bio Announces Partnership with Sequence Me Now to Help Cancer Patients Access Clinical Trials | Press release visual for the Massive Bio and Sequence Me Now partnership announcement, featuring a caregiver and elderly patient reviewing information together on a tablet, symbolizing accessible, personalized support in navigating cancer c... |
| 07.07.2026 | Alberta Cancer Foundation Invests C$35 Million To Advance Cancer Clinical Trials | The Alberta Cancer Foundation announced that it is investing C$35 million to advance cancer clinical trials in Alberta. The funding represents one of the largest clinical trial investments over a five-year period in the foundation’s history... |
| 03.06.2026 | Massive Bio & Optellum Collaborate to Accelerate Clinical Trial Access for Early-Stage NSCLC Patients | Massive Bio and Optellum are joining forces to streamline clinical trial matching for early-stage non-small cell lung cancer patients through AI-driven precision oncology.
Lung cancer risk detection meets precision trial matching, connectin... |
| 31.05.2026 | Massive Bio Announces Next-Generation Reticulum Nexus™ Product Suite at ASCO 2026 | Massive Bio announces the next-generation Reticulum Nexus™ product suite at ASCO 2026. The future of oncology access starts here.
Reticulum Nexus™ brings together six specialized AI agents in a real-time orchestration layer built for precis... |
| 29.05.2026 | Massive Bio Partners with TOUCH BBCA and Navigating Trials to Expand Cancer Patients' Access to Clinical Trials | Massive Bio announces a partnership with TOUCH, The Black Breast Cancer Alliance and Navigating Trials to connect more cancer patients with clinical trial opportunities through AI-powered matching.
AI-powered trial matching now available th... |
| 28.05.2026 | Massive Bio to Unveil Reticulum Nexus™ as the AI Operating System for Oncology Access at ASCO 2026 | Bridging cancer innovation and patient access through a trusted multi-agent platform.
Bridging cancer innovation and patient access through a trusted multi-agent platform.
Cancer patients are not lost because science is absent. They are los... |
| 21.05.2026 | Massive Bio & BeeKeeperAI Use Federated Confidential Computing to Expand Oncology Access in Atlanta's Underserved Areas | Massive Bio and BeeKeeperAI use federated confidential computing to expand oncology trial access across Atlanta's underserved communities.
AI-powered pre-screening infrastructure enables scalable, privacy-preserving clinical trial matching ... |
| 14.05.2026 | Massive Bio and Just Worldwide Announce Strategic Partnership to Connect More Cancer Patients to Clinical Trials | Massive Bio and Just Worldwide have announced a strategic partnership to connect more cancer patients to clinical trial opportunities through patient communities, advocacy groups, and AI-driven trial matching.
Leading global patient engagem... |
| 28.04.2026 | Massive Bio Expands Global Access to Clinical Trials Through AI-Powered Parameterization and Pre-Screening with OpenAI | Massive Bio Expands Global Access to Clinical Trials Through AI-Powered Parameterization and Pre-Screening with OpenAI
Through OpenAI's Impact Hours program, Massive Bio is enabling real-time trial parameterization and free pre-screening se... |
| 09.04.2026 | Massive Bio Publishes Prospective Study on AI-Driven Clinical Trial Matching in 3,804 Cancer Patients | Neuro-symbolic AI achieves 4x faster trial matching with 17,000+ oncologist-confirmed matches, published in ESMO Real World Data and Digital Oncology. BOCA RATON, FL, UNITED STATES, April 9, 2026 /EINPresswire.com/ -- Massive Bio Publishes ... |
| 19.03.2026 | Massive Bio Launches NexusPulse™, the Real-Time AI Signal Engine for Oncology Markets | Massive Bio launches NexusPulse™, its real-time AI signal engine for oncology markets.
Turning real-world clinical and biomarker data into always-on analytics and actionable signals for oncology teams.
NexusPulse is how AI listens to the pu... |
| 02.02.2026 | Massive Bio Launches TrialRelay™ at SCOPE 2026: An Operating System to End 'Referral Black Holes' in Oncology | Massive Bio introduces TrialRelay™, a physician-facing operating system designed to reduce referral friction and improve clinical trial access. Launching at SCOPE 2026, powered by TrialRouter AI.
TrialRelay™, powered by the TrialRouter™ AI ... |
| 17.10.2025 | Massive Bio Calls on Congress to Classify ClinicalTrials.gov as Essential Infrastructure Amid Government Shutdown | Massive Bio Calls on Congress to Classify ClinicalTrials.gov as Essential Infrastructure Amid Government Shutdown
Massive Bio urges Congress to protect ClinicalTrials.gov as essential infrastructure after its shutdown, ensuring patients can... |
| 28.08.2025 | Massive Bio Launches Oracle Cerner App to Simplify Patient Records and Speed Up Clinical Trial Matching | Massive Bio Launches Oracle Cerner App to Simplify Patient Records and Speed Up Clinical Trial Matching
Massive Bio Launches Oracle Cerner App to Simplify Patient Records and Speed Up Clinical Trial Matching BOCA RATON, FL, UNITED STATES, A... |
| 12.08.2025 | Massive Bio and Prognos Health Announce Strategic Partnership to Expand Oncology Access | Massive Bio and Prognos Health Announce Strategic Partnership to Expand Oncology Access
Collaboration leverages Massive Bio's clinical expertise with Prognos Health's real-world data to deliver actionable intelligence for life sciences comp... |
| 31.07.2025 | MASSIVE BIO Delivers on CMS Interoperability Vision with Live Patient Connect App and AI Trial Matching Assistant | MASSIVE BIO Delivers on CMS Interoperability Vision with Live Patient Connect App and AI Trial Matching Assistant
Massive Bio launches Patient Connect & DrArturoAI, delivering on CMS’s vision with AI trial matching, secure data access &... |
| 14.04.2025 | Massive Bio Receives CNIL Certification for GDPR Compliance | Massive Bio is now CNIL-certified, enabling secure processing of medical records in France in full compliance with GDPR.
Massive Bio is now authorized to process medical records in France, marking a major step in AI-driven clinical trial ma... |
| 16.09.2024 | Massive Bio Launches Patient Connect to Personalize Access to Cancer Clinical Trials Globally | Patient Connect
Cancer Clinical Trials BARCELONA, SPAIN, September 16, 2024 /EINPresswire.com/ -- Massive Bio, a global leader in artificial intelligence (AI) for cancer clinical trial enrollment, has announced the launch of Patient Connect... |
| 13.09.2024 | MASSIVE BIO AND FOUNDATION MEDICINE PARTNER TO EXPAND ACCESS TO PRECISION CANCER CARE | Massive Bio and Foundation Medicine, Inc. today announced a strategic collaboration
Massive Bio - FMI
Massive Bio and Foundation Medicine, Inc. today announced a strategic collaboration to increase patient access to cutting edge clinical tr... |
| 03.06.2024 | Massive Bio and Un Ensayo Para Mi Partner to Transform Oncology Trial Access and Deploy AI Technologies Across LATAM | Massive Bio and Un Ensayo Para Mi Partner to Transform Oncology Clinical Trial Access and Deploy AI Technologies Across LATAM at #ASCO24 CHICAGO, ILLINOIS, UNITED STATES OF AMERICA, June 3, 2024 /EINPresswire.com/ -- Massive Bio, renowned l... |
| 02.06.2024 | Massive Bio and Mika Health Combine AI and Next-Generation Sequencing Biomarker Testing to Empower Cancer Patients | Massive Bio and Mika Health Combine AI and Next-Generation Sequencing Biomarker Testing to Empower Cancer Patients CHICAGO, ILLINOIS, UNITED STATES OF AMERICA, June 2, 2024 /EINPresswire.com/ -- Massive Bio, a renowned leader in AI-driven o... |
| 01.06.2024 | Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024 | Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024 CHICAGO, ILLINOIS, UNITED STATES OF AMERICA, June 1, 2024 /EINPresswire.com/ -- Massive Bio, pioneering leader in AI-driven oncology solutions, is excited to... |
| 29.05.2024 | PCC and Massive Bio Validate Existing AI in Groundbreaking and Largest Multi-Sponsor Clinical Trial Matching Study | PCC and Massive Bio Validate Existing AI System in Groundbreaking and Largest Multi-Sponsor Clinical Trial Matching Study CHICAGO, ILLINOIS, UNITED STATES, May 29, 2024 /EINPresswire.com/ -- The Precision Cancer Consortium (PCC), in partner... |
| 07.05.2024 | Massive Bio Unveils Groundbreaking Oncology/Hematology AI Platform at ASCO 2024 | Massive Bio - ASCO 2024
Massive Bio - ASCO 2024 - Chicago
Revolutionizing Oncology/Hematology with AI Driven Personalized Insights for Clinical Trial Accessibility NEW YORK, NEW YORK, UNITED STATES, May 7, 2024 /EINPresswire.com/ -- At the ... |
| 06.02.2024 | Massive Bio Partners with Ollang to Enhance Patient Connectivity Using Advanced Dubbing Technology | Massive Bio Partners with Ollang to Enhance Patient Connectivity Using Advanced Dubbing Technology NEW YORK, NEW YORK, UNITED STATES, February 6, 2024 /EINPresswire.com/ -- Massive Bio, a pivotal player in connecting cancer patients with ta... |
| 30.11.2023 | Massive Bio’s Co-Founder Dr. Arturo Loaiza-Bonilla Participates in Europe’s Leading Health Tech Event | Dr. Arturo Loaiza Bonilla
Health Tech Forward NEW YORK, UNITED STATES, November 30, 2023 /EINPresswire.com/ -- The Health Tech Forward conference, held on November 28-29, 2023 in Warsaw, marked an important gathering in the field of digital... |
| 24.10.2023 | Time Is Running Out to Register for MedCity INVEST Digital Health in Dallas on October 26 | The INVEST Digital Health conference, a collaboration between MedCity News and the Health Wildcatters accelerator, is coming up this Thursday, October 26. Held at Pegasus Park in Dallas, the conference spotlights a wide range of hot topics ... |
| 11.08.2023 | Massive Bio, Teknopol İstanbul'da Yeni Şube Açarak Onkoloji Çözümlerinde İnovasyonu Artırıyor | Massive Bio, Teknopol Istanbul'da yeni şube açıyor.
Massive Bio, Teknopol Istanbul'da yeni şube açıyor. TURKIYE, August 11, 2023/EINPresswire.com/ -- Biyoteknoloji alanında öncü bir şirket olan Massive Bio olarak heyecanla duyuruyoruz ki fa... |
| 11.08.2023 | Massive Bio Expands Operations with New Branch at Teknopol Istanbul, Driving Innovation in Oncology Solutions | Massive Bio opens new branch in Teknopol Istanbul
Massive Bio opens new branch in Teknopol Istanbul NEW YORK, USA, August 11, 2023/EINPresswire.com/ -- Massive Bio, a leading company in the field of biotechnology, is excited to announce the... |
| 04.08.2023 | Massive Bio Partners with Asklepieia, BeStrong, and Open Health Alliance in Greece to Enhance Cancer Clinical Trial | Massive Bio Partners with Asklepieia, BeStrong, and Open Health Alliance in Greece to Enhance Cancer Clinical Trial NEW YORK, NEW YORK, USA, August 4, 2023/EINPresswire.com/ -- Massive Bio and Asklepieia will utilize their innovative techno... |
| 31.07.2023 | 4 Ways Biopharma Is Applying AI/ML to Improve Drug Development Outcomes | Healthcare innovation in drug development intersects with a few critical trends: the rise of artificial intelligence (AI) applications in healthcare—particularly machine learning (ML) and predictive analytics; the need to reduce the costs a... |
| 23.07.2023 | Weekly AiThority Roundup: Biggest Machine Learning, Robotic And Automation Updates – July 3rd Week | This is your AI Weekly Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI), Machine Learning, Robotic Process Automation, Fintech, and human... |
| 20.07.2023 | Massive Bio and CureMatch Announce Groundbreaking Partnership to Revolutionize Cancer Treatment through AI | Massive Bio, an AI-powered platform connecting patients with clinical trials and CureMatch, a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision medicine support for oncology, and have a... |
| 18.07.2023 | Massive Bio and CureMatch Announce Groundbreaking Partnership to Revolutionize Cancer Treatment | Massive Bio & CureMatch Partnership For Cancer Clinical Trial
Massive Bio and CureMatch team up to innovate cancer care, accelerating drug development and improving clinical trial access. NEW YORK, NY, UNITED STATES OF AMERICA, July 18,... |
| 06.06.2023 | MASSIVE BIO JOINS CANCERX AS FOUNDING MEMBER TO ACCELERATE INNOVATION AND AI IMPLEMENTATION IN CANCER CARE | REIGNITING THE CANCER MOONSHOT: MASSIVE BIO JOINS CANCERX AS FOUNDING MEMBER TO ACCELERATE INNOVATION AND AI IMPLEMENTATION IN CANCER CARE NEW YORK, NEW YORK, UNITED STATES, June 6, 2023/EINPresswire.com/ -- Massive Bio, a globally recogniz... |
| 06.06.2023 | Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 6th June 2023 | This is our AI Daily Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI), Machine Learning, Robotic Process Automation, Fintech, and human-s... |
| 05.06.2023 | Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research | Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients, is thrilled to announce a non-exclusive partnership with The Oncology Institute (TOI), a premier provider of cutting-edge cancer ... |
| 05.06.2023 | Massive Bio Launches Revolutionary ChatGPT-Powered Chatbot Platform at ASCO 2023 to Simplify and Expand Access to Oncology Clinical Trials | Massive Bio, a world-renowned provider of personalized oncology solutions, is set to showcase its groundbreaking GPT4 AI chatbots – AskFiona AI and DrArturo AI at ASCO 2023. These innovative, AI-driven solutions will redefine cancer care, e... |
| 05.06.2023 | Precision Cancer Consortium Teams Up with Massive Bio to Utilize AI Analytics and Enhance Clinical Trial Matching for Cancer Patients Worldwide | Massive Bio, a leading artificial intelligence (AI) analytics company specializing in precision oncology, has been selected by the Precision Cancer Consortium (PCC), a collaboration of several global biopharmaceutical companies, to optimize... |
| 05.06.2023 | Massive Bio Joins CancerX as Founding Member to Accelerate Innovation and AI Implementation in Cancer Care | Massive Bio, a globally recognized leader in the oncology space, has proudly announced its appointment as a founding member of CancerX, a groundbreaking initiative endorsed by The White House. This appointment situates Massive Bio at the fo... |
| 01.06.2023 | Massive Bio Launches Revolutionary ChatGPT-Powered Platform at ASCO 2023 to Expand Access to Oncology Clinical Trials | Massie Bio, AI ChatGPT
Massive Bio will showcase its groundbreaking AI chatbots, AskFiona AI and DrArturo AI, at ASCO 2023.
Massive Bio will showcase its groundbreaking AI chatbots, AskFiona AI and DrArturo AI, at ASCO 2023. NEW YORK, NEW Y... |
| 07.04.2023 | Massive Bio accelera la sua espansione nell'Unione Europea, guidata dalle nuove normative sulle sperimentazioni cliniche | Massive Bio, che utilizza AI per abbinare i malati di cancro alle sperimentazioni cliniche, continua a crescere al di fuori degli Stati Uniti ROMA, FLORANCE, ITALY, April 7, 2023/EINPresswire.com/ -- Massive Bio, che utilizza l'intelligenza... |
| 07.04.2023 | Massive Bio מאיץ את התרחבותו באיחוד האירופי, מונע על ידי תקנות ניסויים קליניים חדשות | Massive Bio שבסיסה בניו יורק, המשתמשת בבינה מלאכותית כדי להתאים חולי סרטן לניסויים קליניים, ממשיכה לצמוח מחוץ לארצות הברית. TEL AVIV, TEL AVIV, ISRAEL, April 7, 2023/EINPresswire.com/ -- Massive Bio, המשתמשת בבינה מלאכותית ובשירותי קונסיירז... |
| 07.04.2023 | Massive Bio acelera su expansión en la Unión Europea, impulsada por las nuevas regulaciones de ensayos clínicos | Massive Bio, que utiliza inteligencia artificial para relacionar pacientes con cáncer con ensayos clínicos, continúa creciendo fuera de los Estados Unidos. MADRID, MADRID, SPAIN, April 7, 2023/EINPresswire.com/ -- Massive Bio, que utiliza i... |
| 07.04.2023 | Massive Bio przyspiesza ekspansję w Unii Europejskiej dzięki nowym przepisom dotyczącym badań klinicznych | VARSOVA, POLAND, April 7, 2023/EINPresswire.com/ -- Firma Massive Bio z siedzibą w Nowym Jorku, która wykorzystuje sztuczną inteligencję do dopasowywania pacjentów chorych na raka do badań klinicznych, nadal rozwija się poza Stanami Zjednoc... |
| 22.03.2023 | Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care | -Collaboration will leverage NeoGenomics’ large oncology diagnostic laboratory and Massive Bio’s proven-at-scale proprietary artificial intelligence platform to accelerate drug discovery and optimize patient selection for clinical trials.
M... |
| 27.02.2023 | Clinical Trials Demystified by Massive Bio’s Chief Medical Officer | Arturo Loaiza-Bonilla, MD chief medical officer of Massive Bio, explains why clinical trials can be an important treatment option for cancer patients. NEW YORK, NEW YORK, USA, February 27, 2023 /EINPresswire.com/ -- Cancer is an unfortunate... |
| 22.02.2023 | Massive Bio, dzięki sztucznej inteligencji, wprowadza ponad 100 000 pacjentów chorych na raka do badań klinicznych | Massive Bio, dzięki sztucznej inteligencji, wprowadza ponad 100 000 pacjentów chorych na raka do badań klinicznych.
Massive Bio, dzięki sztucznej inteligencji, wprowadza ponad 100 000 pacjentów chorych na raka do badań klinicznych. VARSOVA,... |
| 22.02.2023 | MASSIVE BIO עוזרת למעל 100,000 חולי סרטן כדי למצוא את הניסוי הקליני שלהם, בעזרת בינה מלאכותית | MASSIVE BIO עוזרת למעל 100,000 חולי סרטן כדי למצוא את הניסוי הקליני שלהם, בעזרת בינה מלאכותית
MASSIVE BIO עוזרת למעל 100,000 חולי סרטן כדי למצוא את הניסוי הקליני שלהם, בעזרת בינה מלאכותית TEL AVIV, ISRAEL, February 22, 2023 /EINPresswire.co... |
| 22.02.2023 | MassiveBio aiuta oltre 100.000 malati di cancro a trovare il loro trial clinico utilizzando un sistema di IA | MassiveBio aiuta oltre 100.000 malati di cancro a trovare il loro trial clinico utilizzando un sistema di IA
MassiveBio aiuta oltre 100.000 malati di cancro a trovare il loro trial clinico utilizzando un sistema di intelligenza artificiale.... |
| 02.02.2023 | The new issue of Massive Bio magazine is now available | The new issue of Massive Bio magazine, which explores the latest developments in oncology and clinical trials, is now available. NEW YORK, NEW YORK, USA, February 2, 2023 /EINPresswire.com/ -- Massive Bio, which uses artificial intelligence... |
| 02.02.2023 | Massive Bio is named to the New York City Digital Health 100 | Massive Bio, which uses AI to match cancer patients to clinical trials, was named to the New York City Digital Health 100 for the second consecutive year. NEW YORK, USA, February 2, 2023 /EINPresswire.com/ -- Massive Bio, a leader in the us... |
| 05.01.2023 | Massive Bio Announces Plans to Expand AI Use in Oncology, from Clinical Trial Matching to Drug Matching and Beyond | Massive Bio, a leader in AI-powered cancer treatment, announced plans to launch a new AI-powered drug matching product in 2023 that will enable oncologists to proactively identify more cancer treatment options for their patients, including ... |
| 28.12.2022 | Decentralized Clinical Trials Could Improve Access to Innovative New Therapies | The rise of ‘virtual’ medical care spurred by the COVID-19 pandemic has helped pave the way for a new approach to conducting clinical trials. NEW YORK, NEW YORK, USA, December 28, 2022 /EINPresswire.com/ -- There’s a quiet revolution underw... |
| 22.12.2022 | Massive Bio Supports Cancer Associations | Massive Bio announced the launch of "Donation for Life," an awareness campaign to support cancer associations and foundations in the United States and Europe. NEW YORK, USA, December 22, 2022 /EINPresswire.com/ -- Massive Bio, whi... |
| 19.12.2022 | People With Cancer Can’t Let Down Their Guard Against COVID-19 | COVID-19 poses a risk to people with cancer, especially those with leukemia, lymphoma, and other cancers of the blood. Taking precautions can lower the risk. NEW YORK, USA, December 19, 2022 /EINPresswire.com/ -- People with cancer who beco... |
| 19.12.2022 | Massive Bio Reaffirms Global Growth Strategy with Key C-Suite Hires and Executive Director Appointments | Fueled by demand from pharmaceutical companies and $16.5 million in new funding to accelerate innovative cancer trial enrollment and oncology solutions using AI NEW YORK, USA, December 19, 2022 /EINPresswire.com/ -- Massive Bio, a leader in... |
| 16.12.2022 | Massive Bio Reaffirms Global Growth Strategy with Key C-Suite Hires and Executive Director Appointments | Fueled by increased demand from pharmaceutical companies and a $16.5 million new funding in 2022 to accelerate innovative cancer trial enrollment and oncology solutions using artificial intelligence
Massive Bio, a leader in AI-powered cance... |
| 15.11.2022 | Massive Bio Launches ‘I Have Cancer’ Campaign | Massive Bio, which uses artificial intelligence to match cancer patients to clinical trials, launches the "I Have Cancer" campaign to raise cancer awareness. NEW YORK, NEW YORK, USA, November 15, 2022 /EINPresswire.com/ -- In keep... |
| 31.10.2022 | Massive Bio Onboards Over 100,000 Cancer Patients to Find Their Clinical Trial, Powered by Artificial Intelligence | Massive Bio, a leader in AI-powered cancer clinical trial enrollment, announced that the company exceeded its goal to onboard 100,000 cancer patients in its platform by the end of 2022 – nine months sooner than expected. The Massive Bio pla... |
| 29.07.2022 | Massive Bio competes with world-class artificial intelligence companies | Massive Bio competes with world-class artificial intelligence companies
Massive Bio’s mission is to provide access to clinical trials for every cancer patient regardless of their location or financial stability, using technology at a global... |
| 15.07.2022 | High level strategy leaders of the pharmaceutical industry gathered at the Guidehouse webinar with Massive Bio | Massive Bio , Selin Kurnaz, PhD
Massive Bio
Massive Bio co-founder and CEO Selin Kurnaz, PhD, participated in roundtable discussion on increasing diversity and inclusion in clinical research. NEW YORK, NEW YORK, UNITED STATES OF AMERICA, Ju... |
| 10.06.2022 | Massive Bio Raises $9 Million to Scale Growth, Fuel Global Expansion of Its AI-Enabled Oncology Clinical Trial Platform | Massive Bio Raises $9 Million to Scale Growth and Fuel Global Expansion of Its AI-Enabled Oncology Clinical Trial Platform
Massive Bio’s mission is to provide access to clinical trials for every cancer patient regardless of their location o... |
| 20.12.2021 | ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder C... | ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, has successfully raised an aggregate $470 million of equity and debt financing in 2021, with $300 million in new debt financing from NantCapital, LLC. With this new f... |
| 07.12.2021 | Massive Bio Launches the Movement to Match 100,000 Cancer Patients to Clinical Trials: 100K SINGULARITY PROGRAM | Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI)-enabled patient-centric clinical trial enrollment for oncology announced the launch of its 100K CANCER CLINICAL TRIAL SINGULARITY PROGRAM, a first-of-its-kin... |
| 31.08.2021 | Massive Bio, Inc. : to Partner With Veterans Prostate Cancer Awareness and Self-Care Catalysts to Accelerate Clinical Trial Enrollment and Digital Health Solutions | Massive Bio today announced it has entered a partnership with Veterans Prostate Cancer Awareness (VPCa), and Self-Care Catalysts to increase clinical trial and real-world evidence research participation in prostate cancer. This will help pu... |
| 03.11.2020 | Massive Bio Secures $2.6M in Financing | Massive Bio, Inc., a NYC-based company that leverages precision medicine and artificial intelligence (AI) to enable patient centric clinical trial enrollment, raised $2.6m in funding.
The round, which brings total funding since launch to $6... |
| - | Massive Bio | “By matching cancer patients with clinical trials that appropriate their cancer diagnosis, Massive Bio is able to provide a superior patient experience.” |
